

Press Release

Astellas and KM Biologics Expiration of Distribution Agreement for Human Vaccines, etc. and Blood Plasma Products

Tokyo and Kumamoto, January 22, 2019 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and KM Biologics Co., Ltd. (President and Representative Director: Toshiaki Nagasato, “KM Biologics”) announced that the agreement for the distribution by Astellas of human vaccines, etc. and blood plasma products (“the products”), which KM Biologics manufactures and sells in Japan, will expire on July 31, 2019. In accordance with the expiration of the agreement, distribution of the products will be transferred as follows.

In terms of human vaccines, etc., Meiji Seika Pharma Co., Ltd. (“Meiji Seika Pharma”), which is an affiliate of Meiji Holdings Co., Ltd. same as KM Biologics, will distribute them as soon as, after April 2019, Astellas’ inventory of those products runs out, based on the distribution agreement concluded by KM Biologics with Meiji Seika Pharma. Meanwhile, Meiji Seika Pharma will provide and collect information on the products from medical institutions from April 1, 2019.

In terms of blood plasma products, Japan Blood Products Organization (“JB”) will distribute them, and provide and collect information on those products from medical institutions from August 1, 2019, based on the distribution agreement concluded by KM Biologics with JB.

Astellas and KM Biologics will work closely with Meiji Seika Pharma and JB to ensure a smooth transfer of the distribution of the products to continue delivering them to patients stably.

List of the major products

“Human vaccines, etc.”

Influenza HA Vaccine “KMB”, Quattrovac, ENCEVAC, Bimmugen, Aimmugen, Inactivated Tissue Culture Rabies Vaccine, and Freeze-dried Mamushi Antivenom “KMB”, etc.

“Blood plasma fraction Formulations”

BOLHEAL[®], Confact[®] F, Novact[®] M, etc.

Sales of the Products by Astellas (Fiscal year ended March 31, 2018)

Approximately 24 billion yen (gross sales basis)

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at <https://www.astellas.com/en>

About KM Biologics

KM Biologics Co., Ltd. is a Kumamoto (Japan) based company that supplies high-quality biological products and services to create a healthy future for people all around the world.

Please visit our website for more information: <http://www.kmbiologics.com/en/>

Cautionary Notes (Astellas)

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473
Company Name
Contact Information